Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease


Harald Hampel, Andrea Vergallo, Mohammad Afshar, Leyla Akman-Anderson, Joaquín Arenas, Norbert Benda, Richard Batrla, Karl Broich, Filippo Caraci, A. Claudio Cuello, Enzo Emanuele, Marion Haberkamp, Steven J. Kiddle, Alejandro Lucía, Mark Mapstone, Steven R. Verdooner, Janet Woodcock, Simone Lista

Research output: Contribution to journalArticle

Abstract

Alzheimer's disease (AD)-a complex disease showing multiple pathomechanistic alterations-is triggered by nonlinear dynamic interactions of genetic/epigenetic and environmental risk factors, which, ultimately, converge into a biologically heterogeneous disease. To tackle the burden of AD during early preclinical stages, accessible blood-based biomarkers are currently being developed. Specifically, next-generation clinical trials are expected to integrate positive and negative predictive blood-based biomarkers into study designs to evaluate, at the individual level, target druggability and potential drug resistance mechanisms. In this scenario, systems biology holds promise to accelerate validation and qualification for clinical trial contexts of use-including proof-of-mechanism, patient selection, assessment of treatment efficacy and safety rates, and prognostic evaluation. Albeit in their infancy, systems biology-based approaches are poised to identify relevant AD "signatures" through multifactorial and interindividual variability, allowing us to decipher disease pathophysiology and etiology. Hopefully, innovative biomarker-drug codevelopment strategies will be the road ahead towards effective disease-modifying drugs.
.

Original languageEnglish
Pages (from-to)177-191
Number of pages15
JournalDialogues in Clinical Neuroscience
Volume21
Issue number2
Publication statusPublished - Jan 1 2019

Fingerprint

Systems Biology
Alzheimer Disease
Biomarkers
Clinical Trials
Nonlinear Dynamics
Drug Resistance
Epigenomics
Pharmaceutical Preparations
Patient Selection
Safety

Keywords

  • Alzheimer’s disease
  • biomarker-drug codevelopment
  • blood-based biomarker
  • clinical trial
  • context of use
  • pathophysiology
  • precision medicine
  • predictive biomarker
  • systems biology

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Hampel, H., Vergallo, A., Afshar, M., Akman-Anderson, L., Arenas, J., Benda, N., ... Lista, S. (2019). Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
. Dialogues in Clinical Neuroscience, 21(2), 177-191.

Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
. / Hampel, Harald; Vergallo, Andrea; Afshar, Mohammad; Akman-Anderson, Leyla; Arenas, Joaquín; Benda, Norbert; Batrla, Richard; Broich, Karl; Caraci, Filippo; Cuello, A. Claudio; Emanuele, Enzo; Haberkamp, Marion; Kiddle, Steven J.; Lucía, Alejandro; Mapstone, Mark; Verdooner, Steven R.; Woodcock, Janet; Lista, Simone.

In: Dialogues in Clinical Neuroscience, Vol. 21, No. 2, 01.01.2019, p. 177-191.

Research output: Contribution to journalArticle

Hampel, H, Vergallo, A, Afshar, M, Akman-Anderson, L, Arenas, J, Benda, N, Batrla, R, Broich, K, Caraci, F, Cuello, AC, Emanuele, E, Haberkamp, M, Kiddle, SJ, Lucía, A, Mapstone, M, Verdooner, SR, Woodcock, J & Lista, S 2019, 'Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
', Dialogues in Clinical Neuroscience, vol. 21, no. 2, pp. 177-191.
Hampel H, Vergallo A, Afshar M, Akman-Anderson L, Arenas J, Benda N et al. Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
. Dialogues in Clinical Neuroscience. 2019 Jan 1;21(2):177-191.
Hampel, Harald ; Vergallo, Andrea ; Afshar, Mohammad ; Akman-Anderson, Leyla ; Arenas, Joaquín ; Benda, Norbert ; Batrla, Richard ; Broich, Karl ; Caraci, Filippo ; Cuello, A. Claudio ; Emanuele, Enzo ; Haberkamp, Marion ; Kiddle, Steven J. ; Lucía, Alejandro ; Mapstone, Mark ; Verdooner, Steven R. ; Woodcock, Janet ; Lista, Simone. / Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
. In: Dialogues in Clinical Neuroscience. 2019 ; Vol. 21, No. 2. pp. 177-191.
@article{af7a84c2b46b4721a9fa8791c9255797,
title = "Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
",
abstract = "Alzheimer's disease (AD)-a complex disease showing multiple pathomechanistic alterations-is triggered by nonlinear dynamic interactions of genetic/epigenetic and environmental risk factors, which, ultimately, converge into a biologically heterogeneous disease. To tackle the burden of AD during early preclinical stages, accessible blood-based biomarkers are currently being developed. Specifically, next-generation clinical trials are expected to integrate positive and negative predictive blood-based biomarkers into study designs to evaluate, at the individual level, target druggability and potential drug resistance mechanisms. In this scenario, systems biology holds promise to accelerate validation and qualification for clinical trial contexts of use-including proof-of-mechanism, patient selection, assessment of treatment efficacy and safety rates, and prognostic evaluation. Albeit in their infancy, systems biology-based approaches are poised to identify relevant AD {"}signatures{"} through multifactorial and interindividual variability, allowing us to decipher disease pathophysiology and etiology. Hopefully, innovative biomarker-drug codevelopment strategies will be the road ahead towards effective disease-modifying drugs.
.",
keywords = "Alzheimer’s disease, biomarker-drug codevelopment, blood-based biomarker, clinical trial, context of use, pathophysiology, precision medicine, predictive biomarker, systems biology",
author = "Harald Hampel and Andrea Vergallo and Mohammad Afshar and Leyla Akman-Anderson and Joaqu{\'i}n Arenas and Norbert Benda and Richard Batrla and Karl Broich and Filippo Caraci and Cuello, {A. Claudio} and Enzo Emanuele and Marion Haberkamp and Kiddle, {Steven J.} and Alejandro Luc{\'i}a and Mark Mapstone and Verdooner, {Steven R.} and Janet Woodcock and Simone Lista",
year = "2019",
month = "1",
day = "1",
language = "English",
volume = "21",
pages = "177--191",
journal = "Dialogues in Clinical Neuroscience",
issn = "1294-8322",
publisher = "Servier International",
number = "2",

}

TY - JOUR

T1 - Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease


AU - Hampel, Harald

AU - Vergallo, Andrea

AU - Afshar, Mohammad

AU - Akman-Anderson, Leyla

AU - Arenas, Joaquín

AU - Benda, Norbert

AU - Batrla, Richard

AU - Broich, Karl

AU - Caraci, Filippo

AU - Cuello, A. Claudio

AU - Emanuele, Enzo

AU - Haberkamp, Marion

AU - Kiddle, Steven J.

AU - Lucía, Alejandro

AU - Mapstone, Mark

AU - Verdooner, Steven R.

AU - Woodcock, Janet

AU - Lista, Simone

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Alzheimer's disease (AD)-a complex disease showing multiple pathomechanistic alterations-is triggered by nonlinear dynamic interactions of genetic/epigenetic and environmental risk factors, which, ultimately, converge into a biologically heterogeneous disease. To tackle the burden of AD during early preclinical stages, accessible blood-based biomarkers are currently being developed. Specifically, next-generation clinical trials are expected to integrate positive and negative predictive blood-based biomarkers into study designs to evaluate, at the individual level, target druggability and potential drug resistance mechanisms. In this scenario, systems biology holds promise to accelerate validation and qualification for clinical trial contexts of use-including proof-of-mechanism, patient selection, assessment of treatment efficacy and safety rates, and prognostic evaluation. Albeit in their infancy, systems biology-based approaches are poised to identify relevant AD "signatures" through multifactorial and interindividual variability, allowing us to decipher disease pathophysiology and etiology. Hopefully, innovative biomarker-drug codevelopment strategies will be the road ahead towards effective disease-modifying drugs.
.

AB - Alzheimer's disease (AD)-a complex disease showing multiple pathomechanistic alterations-is triggered by nonlinear dynamic interactions of genetic/epigenetic and environmental risk factors, which, ultimately, converge into a biologically heterogeneous disease. To tackle the burden of AD during early preclinical stages, accessible blood-based biomarkers are currently being developed. Specifically, next-generation clinical trials are expected to integrate positive and negative predictive blood-based biomarkers into study designs to evaluate, at the individual level, target druggability and potential drug resistance mechanisms. In this scenario, systems biology holds promise to accelerate validation and qualification for clinical trial contexts of use-including proof-of-mechanism, patient selection, assessment of treatment efficacy and safety rates, and prognostic evaluation. Albeit in their infancy, systems biology-based approaches are poised to identify relevant AD "signatures" through multifactorial and interindividual variability, allowing us to decipher disease pathophysiology and etiology. Hopefully, innovative biomarker-drug codevelopment strategies will be the road ahead towards effective disease-modifying drugs.
.

KW - Alzheimer’s disease

KW - biomarker-drug codevelopment

KW - blood-based biomarker

KW - clinical trial

KW - context of use

KW - pathophysiology

KW - precision medicine

KW - predictive biomarker

KW - systems biology

UR - http://www.scopus.com/inward/record.url?scp=85073655577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073655577&partnerID=8YFLogxK

M3 - Article

C2 - 31636492

AN - SCOPUS:85073655577

VL - 21

SP - 177

EP - 191

JO - Dialogues in Clinical Neuroscience

JF - Dialogues in Clinical Neuroscience

SN - 1294-8322

IS - 2

ER -